Why are GLP-1 medicines not recommended in pregnancy?

Pregnant and breastfeeding participants are systematically excluded from pivotal trials of these medicines, for ethical reasons, so there is no purposeful human safety evidence to support use in pregnancy. UK SmPCs reflect this evidence gap by advising against use rather than by citing a specific demonstrated harm. This site carries a separate plain-English explainer on pregnancy and GLP-1 use; this entry focuses on the regulatory and evidentiary basis for the exclusion.

How long before trying to conceive should therapy be stopped?

UK SmPCs typically advise discontinuation prior to planned conception, though the specific interval reflects each product's own labelling and pharmacokinetics. The precise timing for an individual is a decision for the prescriber managing pregnancy planning, not a self-directed calculation.

What is known about outcomes if pregnancy occurs unexpectedly during treatment?

Because purposeful pregnancy-exposure trials do not exist for these medicines, evidence on outcomes following unintentional in-pregnancy exposure remains limited. Suspected or confirmed pregnancy during incretin therapy should prompt urgent review with the prescriber rather than any self-managed decision about continuing or stopping treatment.

Is breastfeeding also affected, and why?

Yes — breastfeeding is also an exclusion in UK SmPCs for the licensed incretin medicines, again reflecting the systematic exclusion of breastfeeding participants from pivotal trials rather than a specific demonstrated harm to infants. Anyone breastfeeding who is considering or already using these medicines should discuss this directly with a qualified clinician.

Pregnancy and breastfeeding exclusions

What is known

Pregnancy and breastfeeding are exclusion criteria in pivotal trials.
UK SmPCs typically advise discontinuation prior to planned conception.

What remains uncertain

Specific outcomes after unintentional in-pregnancy exposure remain limited.

Trial limitations

No purposeful pregnancy-exposure trials exist for ethical reasons.

FAQs

Why are GLP-1 medicines not recommended in pregnancy?: Pregnant and breastfeeding participants are systematically excluded from pivotal trials of these medicines, for ethical reasons, so there is no purposeful human safety evidence to support use in pregnancy. UK SmPCs reflect this evidence gap by advising against use rather than by citing a specific demonstrated harm. This site carries a separate plain-English explainer on pregnancy and GLP-1 use; this entry focuses on the regulatory and evidentiary basis for the exclusion.
How long before trying to conceive should therapy be stopped?: UK SmPCs typically advise discontinuation prior to planned conception, though the specific interval reflects each product's own labelling and pharmacokinetics. The precise timing for an individual is a decision for the prescriber managing pregnancy planning, not a self-directed calculation.
What is known about outcomes if pregnancy occurs unexpectedly during treatment?: Because purposeful pregnancy-exposure trials do not exist for these medicines, evidence on outcomes following unintentional in-pregnancy exposure remains limited. Suspected or confirmed pregnancy during incretin therapy should prompt urgent review with the prescriber rather than any self-managed decision about continuing or stopping treatment.
Is breastfeeding also affected, and why?: Yes — breastfeeding is also an exclusion in UK SmPCs for the licensed incretin medicines, again reflecting the systematic exclusion of breastfeeding participants from pivotal trials rather than a specific demonstrated harm to infants. Anyone breastfeeding who is considering or already using these medicines should discuss this directly with a qualified clinician.